Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) issued its quarterly earnings data on Thursday. The biopharmaceutical company reported ($1.72) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($1.72), Bloomberg Earnings reports. During the same quarter in the prior year, the business earned ($1.46) earnings per share.

Shares of Ultragenyx Pharmaceutical (RARE) traded down 4.36% during mid-day trading on Thursday, reaching $67.74. 296,745 shares of the company traded hands. The firm has a 50 day moving average of $64.32 and a 200-day moving average of $67.77. Ultragenyx Pharmaceutical has a 52 week low of $51.67 and a 52 week high of $91.35. The stock’s market capitalization is $2.87 billion.

In related news, VP Theodore Alan Huizenga sold 480 shares of the firm’s stock in a transaction dated Friday, May 26th. The stock was sold at an average price of $57.46, for a total transaction of $27,580.80. Following the completion of the transaction, the vice president now directly owns 9,366 shares in the company, valued at approximately $538,170.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 9.20% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/07/27/ultragenyx-pharmaceutical-inc-nasdaqrare-issues-quarterly-earnings-results.html.

Several brokerages have commented on RARE. BidaskClub upgraded shares of Ultragenyx Pharmaceutical from a “hold” rating to a “buy” rating in a report on Tuesday. Sanford C. Bernstein initiated coverage on shares of Ultragenyx Pharmaceutical in a research note on Thursday. They issued a “market perform” rating and a $72.00 price target for the company. ValuEngine upgraded shares of Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Thursday, June 22nd. Zacks Investment Research upgraded shares of Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Tuesday, July 18th. Finally, Jefferies Group LLC reiterated a “hold” rating and issued a $68.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Friday, July 14th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and nine have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $84.80.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

Earnings History for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.